Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Adenosine 30mg/10ml Solution for Infusion

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Adenosine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Adenosine

Equivalent medicines (same active substance, strength and form)

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for The name of your medicine is Adenosine Infusion. The active ingredient in your medicine is adenosine. Adenosine belongs to a group of medicines called coronary vasodilators. This medicine is for diagnostic use only. Adenosine Infusion is given before a test called "myocardial perfusion imaging" to look at your heart. During this test you are given a medicine called a "radiopharmaceutical". Adenosine Infusion works by opening up your heart's blood vessels and allowing blood to flow more freely. This allows the" radiopharmaceutical" medicine to get into your heart. The doctor can see your heart and assess your heart condition. This is used if you are not capable of exercise or if an exercise stress test is not possible.

  • a left-right shunt in your heart. This will mean blood goes directly from the left side of your heart to the right side
  • narrowing of the left main artery supplying blood to your heart (left main coronary stenosis)
  • had a recent heart attack, severe heart failure or you have had a heart transplant in the last year
  • an unusual heart rhythm. For example, your heartbeat is very fast or uneven (atrial fibrillation or atrial flutter) and in particular if you have a condition where your heart has abnormal electrical activity ('accessory conduction pathway')
  • any minor problem with your heart (first degree atrioventricular block or a bundle branch block). These conditions may be temporarily aggravated when you are given Adenosine Infusion. Talk to your doctor immediately if:
  • You experience signs of stroke. This may present itself as a sudden numb or weak feeling in the face, arms, or legs. Other signs include feeling confused, problems with sight, walking, coordination or balance, problems in saying words or slurring of speech
  • You experience signs of heart attack (myocardial infarction). Severe chest pain is the usual main symptom. The pain may also travel up into your jaw, and down your left arm, or down both arms. You may also sweat, feel sick, and feel faint. A small heart attack (myocardial infarction) occasionally happens without causing pain (a 'silent myocardial infarction'). It may be truly pain-free, or sometimes the pain is mild and you may think it is just heartburn or 'wind'. If you are not sure if any of the above apply to you, talk to your doctor or nurse before being given Adenosine Infusion. Children and adolescents Adenosine Infusion use in children and adolescents has not been sufficiently studied Taking other medicines Please tell your doctor or nurse if you are taking or have recently taken or might take any other medicines. This includes medicines obtained without a prescription, including herbal medicines. This is because Adenosine Infusion can affect the way some 2. Before you are given Adenosine Infusion other medicines work. Also some medicines can Do not have this medicine and tell your doctor affect the way Adenosine Infusion works. if you: In particular, check with your doctor or nurse if you
  • are allergic (hypersensitive) to adenosine or to any are taking any of the following: of the other ingredients in this medicine (listed in
  • Dipyridamole (medicine used to thin the blood). section 6) Make sure your doctor knows you are taking Signs of an allergic reaction include: a rash, dipyridamole. Your doctor may tell you to stop swallowing or breathing problems, swelling of taking dipyridamole 24 hours before you are given your lips, face, throat or tongue Adenosine Infusion or you may be given a much
  • have very low blood pressure (severe hypotension) lower dose of Adenosine Infusion
  • have unstable angina which is not controlled by
  • Aminophylline, theophylline or other xanthines treatment with medicine (medicines used to help breathing). Make sure
  • have asthma or any other severe breathing you tell your doctor you are taking any of these problem medicines. Your doctor may tell you to stop taking
  • are taking a medicine called dipyridamole (used to them 24 hours before you are given Adenosine thin the blood) Infusion.
  • have a type of heart failure where your heart is not Taking Adenosine Infusion with food and drink pumping out enough blood Food and drink containing xanthines such as tea,
  • have problems with your heart rhythm and do coffee chocolate and cola, should be avoided for not have a pacemaker (second or third degree at least 12 hours before you are given Adenosine atrioventricular block, sick sinus syndrome) Infusion.
  • have been told you have 'Long QT syndrome'. Pregnancy and breast-feeding This is a rare heart problem that can lead to a fast Talk to your doctor or nurse before having this heartbeat and fainting. medicine if: Do not have this medicine if any of the above apply
  • You are pregnant, might become pregnant, or to you. If you are not sure, talk to your doctor or nurse think that you may be pregnant. You should not be before you are given Adenosine Infusion. given Adenosine Infusion unless clearly necessary Warnings and Precautions
  • You are breast-feeding. You should not be given Check with your doctor or nurse before you have Adenosine Infusion. Adenosine Infusion if you have: Ask your doctor or nurse for advice before taking any
  • low blood volume (hypovolaemia) that is not medicine if you are pregnant or breast-feeding. adequately corrected by treatment with medicines Important information about some of the
  • problems with a part of your nervous system called ingredients of Adenosine Infusion the 'autonomic nervous system'. This medicinal product contains approximately
  • narrowing of the main arteries in the neck (carotid 36mg sodium per vial (10ml). This should be taken artery). This means that not enough blood is into consideration by patients on a controlled getting to the brain (cerebrovascular insufficiency) sodium diet.
  • or have ever had fits or convulsions 3. How you will be given Adenosine Infusion
  • difficulty in breathing (bronchospasm)
  • heart disease due to narrowing of your heart
  • Adenosine Infusion is a medicine for use in hospitals valves (stenotic valvular heart disease)
  • Adenosine Infusion will be given to you by a doctor
  • inflammation of the membrane surrounding your or nurse as an injection. The injection will be into heart (pericarditis) or a build-up of the fluid around one of your veins. It will be given over a period of your heart (pericardial effusion) time (this is called an intravenous infusion) ✂ INFORMATION FOR HEALTHCARE PROFESSIONALS Adenosine 30mg/10ml Solution for Infusion Please refer to the Summary of Product Characteristics (SmPC) for further details on this product. Qualitative and Quantitative Composition Each vial contains 30mg of adenosine per 10ml (3mg/ml). Excipient: each vial contains approximately 36 mg of sodium per vial (10ml). For a full list of excipients, see SmPC Section 6.1. Pharmaceutical Form Solution for infusion. A clear, colourless solution free from visible particles Therapeutic indications Intravenous (IV) adenosine infusion is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging in patients who cannot exercise adequately or for whom exercise is inappropriate. Posology and method of administration Adenosine infusion is intended for use in hospitals with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary. It should be administered following the same procedure as for exercise testing where facilities for cardiac monitoring and cardio-respiratory resuscitation are available. During administration of adenosine infusion continuous ECG control is necessary as lifethreatening arrhythmia might occur. Heart rate and blood pressure should be monitored every minute. Posology: Adults: 1. Adenosine Infusion should be administered undiluted as a continuous peripheral intravenous infusion at a dose of 140 μg/kg/min for six minutes using an infusion pump. Separate venous sites for Adenosine Infusion and radionuclide administration are recommended to avoid an adenosine bolus effect. 2. After three minutes of Adenosine Infusion, the radionuclide is injected to ensure sufficient time for peak coronary blood flow to occur. The optimal vasodilator protocol is achieved with six minutes of Adenosine Infusion. 3. To avoid an adenosine bolus effect, blood pressure should be measured in the arm opposite to the adenosine infusion. The table below is given as a guide for adjustment of the infusion rate of undiluted Adenosine Infusion, in line with bodyweight (total dose 0.84 mg/kg).

Patient Weight (kg) Infusion Rate (ml/min) 2.1 45-49 2.3 50-54 2.6 55-59 2.8 60-64 3.0 65-69 3.3 70-74 3.5 75-79 3.8 80-84 4.0 85-89 4.2 90-94 4.4 95-99 4.7 100-104 Paediatric population: The safety and efficacy of adenosine in children aged 0 to 18 years have not been established. Currently available data are described in section 5.1 (SmPC) but no recommendation on a posology can be made. Elderly: See dosage recommendations for adults. Pharmaceutical Particulars List of excipients Sodium chloride Water for injections Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Shelf life Unopened: 36 months. The product should be used immediately after opening. Special precautions for storage Store below 25°C. Do not refrigerate. Nature and contents of container Clear, neutral type I glass vials (10ml) sealed with chlorobutyl rubber closures. Packs of 6 vials packed in a PVC tray in a cardboard carton. Special precautions for disposal Do not use if any particles or discolouration are noticed in the solution. Any unused product or waste material should be disposed of in accordance with local requirements Marketing Authorisation Holder Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK Marketing Authorisation Number PL 29831/0456 Date of Revision of Text: 6/2023

105569/8

Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.

Customer

Wockhardt UK Limited

Colours Used

Description

Adenosine Infusion 3mg/ml

Black

Item Code

105569/8

Keyline (Non-Printing)

Profile

n/a

Technical Info (Non-Printing)

Size

148 x 460mm

Text Free Area (Non-Printing)

Min.Point Size

Other

Market

UK

Language

English

Standard 116

Barcode Proof By

CJE

Proof No.

1

Date

03/07/2023

Body Text Fonts:

Myriad Pro

Body Text Ctd.

Actual Min Point Size

8 pt

Cirrus_Info_Box

Very rare side effects (may affect up to 1 in 10,000 people)

  • Severe breathlessness or problems in breathing
  • Redness, pain or swelling at the site of injection. Other side effects (frequency cannot be estimated from the available data)
  • Allergic reactions including swelling of the face or throat, and skin reactions such as hives or rash
  • Severe heart problems which can be fatal (asystole) or uneven heartbeat
  • Fits (convulsions)
  • Fainting
  • Stopping breathing (respiratory arrest)
  • Feeling sick (nausea) or being sick (vomiting)
  • Spasm of the artery in the heart which may lead to a heart attack. If any of the above side effects get worse, tell your doctor or nurse immediately and they will decide if you should continue the infusion or not. The side effects normally settle within seconds or minutes after the infusion is finished but you should tell your doctor or nurse if any of them happen. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

How to take it

If you are not sure why you are being given Adenosine Infusion or have any questions about how much Adenosine Infusion is being given to you, speak to your doctor or nurse. Adults (including the elderly)

  • The dose is calculated according to your weight
  • The usual dose is 140 micrograms per kilogram of bodyweight, per minute. This is given over a period of six minutes through an infusion pump (a slow injection into a vein)
  • The dose of Adenosine Infusion is not changed if you have liver or kidney problems. If you have more Adenosine Infusion than you should As this medicine is given to you by your doctor or nurse. It is unlikely that you will be given too much. You doctor will carefully work out how much Adenosine Infusion you should be given. If you have more of this medicine than you should, the following effects may happen:
  • Very low blood pressure (severe hypotension)
  • Slow heartbeat (bradycardia)
  • A heart problem (asystole). Your doctor will be monitoring your heart throughout the procedure. As the length of time Adenosine stays in the blood is very short, any side effects of too much Adenosine would quickly stop when the infusion is stopped. Sometimes you may need an injection of a medicine called aminophylline or theophylline to help with any side effects. If you have any further questions on the use of this medicine, ask your doctor or nurse.

Possible side effects

Like all medicines, Adenosine Infusion can cause side effects, although not everybody gets them. While you are being given Adenosine Infusion you may have some of the following side effects: If any of the following side effects get worse, tell your doctor or nurse immediately and they will decide if you should continue the infusion or not. The side effects normally settle within seconds or minutes after the infusion is finished but you should tell your doctor or nurse if any of them happen. Very common (may affect more than 1 in 10 people)

  • Reddening of the skin with a feeling of heat (flushing)
  • Shortness of breath or the urge to breathe deeply (dyspnoea)
  • Headache
  • Chest pain or pressure on the chest
  • Abdominal discomfort. Common (may affect up to 1 in 10 people)
  • Feeling dizzy, or light-headed
  • Unusual skin sensations such as numbness, tingling, prickling, burning or creeping on the skin (paraesthesia)
  • Low blood pressure
  • A heart problem called an atrioventricular block
  • Fast or irregular heartbeat (disorders of cardiac rhythm)
  • Dry mouth
  • Discomfort in throat, jaw or neck. Uncommon (may affect up to 1in 100 people)
  • Metallic taste in your mouth
  • Sweating
  • Discomfort in leg, arm or back
  • Feeling of weakness or pain, or of general discomfort
  • Feeling nervous
  • Slow heartbeat (bradycardia). Rare (may affect up to 1 in 1,000 people)
  • Difficulty in breathing (bronchospasm)
  • Blocked nose
  • Feeling drowsy
  • Blurred vision
  • Ringing in the ear (tinnitus)
  • Feeling a sudden need to urinate
  • Nipple discomfort
  • Tremors.

6. Further information What Adenosine 30mg/10ml Solution for Infusion contains The active ingredient is adenosine. Each 10ml vial contains 30mg of adenosine (3mg/ml). The other ingredients are sodium chloride and water for injections. What Adenosine 30mg/10ml Solution for Infusion looks like and the contents of the pack Adenosine is a clear, colourless solution for infusion. Adenosine 30mg/10ml Solution for Infusion is available in packs of 6 single use glass vials. Marketing Authorisation Holder Wockhardt UK Ltd, Ash Road North, Wrexham LL13 9UF, UK Manufacturer CP Pharmaceuticals Ltd, Ash Road North, Wrexham LL13 9UF, UK Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK only). Please be ready to give the following information: Product name Reference number Adenosine 30mg/10ml PL 29831/0456 Solution for Infusion This is a service provided by the Royal National Institute of Blind People. This leaflet was last revised in 06/2023

105569/8 ✂

Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.

Customer

Wockhardt UK Limited

Colours Used

Description

Adenosine Infusion 3mg/ml

Black

Item Code

105569/8

Keyline (Non-Printing)

Profile

n/a

Technical Info (Non-Printing)

Size

148 x 460mm

Text Free Area (Non-Printing)

Min.Point Size

Other

Market

UK

Language

English

Standard 116

Barcode Proof By

CJE

Proof No.

1

Date

03/07/2023

Body Text Fonts:

Myriad Pro

Body Text Ctd.

Actual Min Point Size

8 pt

Cirrus_Info_Box

How to store it

Adenosine Infusion Keep out of the reach and sight of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store below 25°C. Do not refrigerate. The product should be used immediately after opening. Do not use if any particles or discolouration are noticed in the solution. Medicines should not be disposed of via wastewater or household waste. Your doctor or nurse will dispose of any unused medicine. These measures will help protect the environment.

  • Your heart rate and blood pressure will be closely monitored.

Frequently asked questions about Adenosine 30mg/10ml Solution for Infusion

How do I take Adenosine 30mg/10ml Solution for Infusion?

Adenosine 30mg/10ml Solution for Infusion comes as infusion containing 30mg / 10ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Adenosine 30mg/10ml Solution for Infusion?

The active substance in Adenosine 30mg/10ml Solution for Infusion is adenosine.

Are there equivalent medicines to Adenosine 30mg/10ml Solution for Infusion?

Medicines with the same active substance, strength and form include: Adenosine 30 mg/10 ml solution for infusion, Adenosine 30mg/10ml Solution for Infusion. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Adenosine 30mg/10ml Solution for Infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Adenosine 30mg/10ml Solution for Infusion without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Adenosine (6 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Intravenous (IV) adenosine infusion is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging in patients who cannot exercise adequately or for whom exercise is inappropriate.

4.2. Posology and method of administration

Adenosine infusion is intended for use in hospitals with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary.

It should be administered following the same procedure as for exercise testing where facilities for cardiac monitoring and cardio-respiratory resuscitation are available. During administration of adenosine infusion continuous ECG control is necessary as life-threatening arrhythmia might occur. Heart rate and blood pressure should be monitored every minute.

Posology:

Adults:

1. Adenosine Infusion should be administered undiluted as a continuous peripheral intravenous infusion at a dose of 140 µg/kg/min for six minutes using an infusion pump. Separate venous sites for Adenosine Infusion and radionuclide administration are recommended to avoid an adenosine bolus effect.

2. After three minutes of Adenosine Infusion, the radionuclide is injected to ensure sufficient time for peak coronary blood flow to occur. The optimal vasodilator protocol is achieved with six minutes of Adenosine Infusion.

3. To avoid an adenosine bolus effect, blood pressure should be measured in the arm opposite to the adenosine infusion.

The table below is given as a guide for adjustment of the infusion rate of undiluted adenosine infusion, in line with bodyweight (total dose 0.84 mg/kg).

Patient Weight (kg)

Infusion Rate (ml/min)

45-49

2.1

50-54

2.3

55-59

2.6

60-64

2.8

65-69

3.0

70-74

3.3

75-79

3.5

80-84

3.8

85-89

4.0

90-94

4.2

95-99

4.4

100-104

4.7

Paediatric population

The safety and efficacy of adenosine in children aged 0 to 18 years have not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.

Elderly:

See dosage recommendations for adults.

4.3. Contraindications

Adenosine infusion is contraindicated in patients suffering from:

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

- Second or third degree atrioventricular (AV) block, sick sinus syndrome, except in patients with a functioning artificial pacemaker.

- Long QT syndrome.

- Severe hypotension.

- Unstable angina not successfully stabilised with medical therapy.

- Decompensated states of heart failure.

- Chronic obstructive lung disease with evidence of bronchospasm (e.g. asthma bronchiale).

- Concomitant use of dipyridamole (see section 4.5)

4.4. Special warnings and precautions for use

Adenosine is intended for use in a hospital setting with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary. During administration, continuous ECG monitoring is necessary as life-threatening arrhythmia might occur. (section 4.2).

Because it has the potential to cause significant hypotension, adenosine infusion should be used with caution in patients with left main coronary stenosis, uncorrected hypovolemia, stenotic valvular heart disease, left to right shunt, pericarditis or pericardial effusion, autonomic dysfunction or stenotic carotid artery disease with cerebrovascular insufficiency. Adenosine infusion should be discontinued in any patient who develops persistent or symptomatic hypotension. There have been reports of cerebrovascular accident/transient ischemic attack, secondary to the haemodynamic effects of adenosine.

There have been reports of myocardial infarction shortly after use of Adenosine Infusion. Adenosine Infusion should be used with caution in patients with recent myocardial infarction, severe heart failure. Adenosine should be used with caution in patients with minor conduction defects (first degree A-V block, bundle branch block) that could be transiently aggravated during infusion.

Adenosine may trigger convulsions in patients who are susceptible to convulsions.

Adenosine should be used with caution in patients with atrial fibrillation or flutter and especially in those with an accessory by-pass tract since particularly the latter may develop increased conduction down the anomalous pathway.

Rare cases of severe bradycardia have been reported. Some occurred in early post-transplant patients; in the other cases occult sino-atrial disease was present. The occurrence of severe bradycardia should be taken as a warning of underlying disease and should lead to treatment discontinuation. Severe bradycardia would favour the occurrence of torsades de pointes, especially in patients with prolonged QT intervals. But to date, no case of torsades de pointes has been reported when adenosine is continuously infused.

The occurrence of respiratory failure (potentially fatal), asystole/cardiac arrest (potentially fatal), angina, severe bradycardia or severe hypotension should also lead to treatment discontinuation.

In patients with recent heart transplantation (less than 1 year) an increased sensitivity of the heart to adenosine has been observed.

Adenosine may precipitate or aggravate bronchospasm (see sections 4.3 and 4.8).

Adenosine infusion contains approximately 36mg sodium per vial (10ml). To be taken into consideration by patients on a controlled sodium diet.

4.5. Interaction with other medicinal products and other forms of interaction

Dipyridamole inhibits adenosine cellular uptake and metabolism, and potentiates the action of adenosine. In one study dipyridamole was shown to produce a 4 fold increase in adenosine actions. It is therefore suggested that adenosine infusion should not be administered to patients receiving dipyridamole; if use of adenosine infusion is essential, dipyridamole should be stopped 24 hours before hand, or the dose of adenosine should be greatly reduced.

Aminophylline, theophylline and other xanthines are competitive adenosine antagonists and should be avoided for 24 hours prior to use of Adenosine Infusion.

Food and drinks containing xanthines (tea, coffee, chocolate and cola) should be avoided for at least 12 hours prior to use of Adenosine Infusion.

Adenosine may interact with drugs tending to impair cardiac conduction.

4.6. Fertility, pregnancy and lactation

Pregnancy:

There are no or limited amount of data from the use of adenosine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Adenosine is not recommended during pregnancy unless the physician considers the benefits to outweigh the potential risks.

Breast-feeding

It is unknown whether adenosine metabolites are excreted in human milk.

Adenosine infusion should not be used during breast-feeding.

4.7. Effects on ability to drive and use machines

Not relevant.

4.8. Undesirable effects

Effects related to the known pharmacology of adenosine are frequent, but usually self-limiting and of short duration. Discontinuation of infusion may be necessary if the effect is intolerable.

Methylxanthines, such as IV aminophylline or theophylline have been used to terminate persistent side effects (50-125 mg by slow intravenous injection).

Adverse events are ranked under the heading of the frequency:

Very common (>1/10), Common (≥1/100, <1/10), Uncommon (≥1/1,000, <1/100), Rare (≥1/10,000, <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from available data).

Immune system disorders:

• Not known: anaphylactic reaction (including angioedema and skin reactions such as urticaria and rash).

Cardiac Disorders:

• Common: ST segment depression, sustained or non-sustained ventricular tachycardia, AV block (see section 4.4).

If sustained second or third degree AV block develops the infusion should be discontinued. If first degree AV block occurs, the patient should be observed carefully as a quarter of patients will progress to a higher degree of block.

• Uncommon: bradycardia sometimes severe (see section 4.4)

• Not known: asystole/cardiac arrest (sometimes fatal, especially in patients with underlying ischemic heart disease/cardiac disorders, see section 4.4): sinus tachycardia, atrial fibrillation, ventricular fibrillation, arteriospasm coronary which may lead to myocardial infarction.

Nervous system disorders

• Very common: headacheCommon: dizziness, light-headedness, paraesthesia

• Rare: tremor, drowsiness

• Not known: loss of consciousness / syncope, convulsions, especially in predisposed patients (see section 4.4)

Eye disorders

• Rare: blurred vision

Ear and labyrinth disorders:

• Rare: tinnitus

Respiratory, thoracic and mediastinal disorders:

• Very common: dyspnea (or the urge to breathe deeply)

• Rare: bronchospasm (see section 4.4), nasal congestion

• Very rare: respiratory failure (see section 4.4)

• Not known: apnea/respiratory arrest

Cases with fatal outcome of respiratory failure, of bronchospasm, and of apnea/respiratory arrest have been reported.

Gastro-intestinal disorders:

• Very common: abdominal discomfort

• Common: dry mouth

• Uncommon: metallic taste

• Not known: nausea, vomiting.

Renal and Urinary disorders:

• Rare: urinary urgency

Vascular disorders:

• Very common: flushing

• Common: hypotension, sometimes severe (see section 4.4)

General disorders and administration site conditions:

• Very common: chest pain or pressure, feeling of thoracic constriction/oppression

• Common: throat, neck and jaw discomfort

• Uncommon: sweating, discomfort in the leg, arm or back, feeling of general discomfort weakness/pain

• Very rare: injection site reactions

Reproductive system and breast disorders:

• Rare: nipple discomfort

Psychiatric disorders:

• Uncommon: nervousness

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA

Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Overdosage would cause severe hypotension, bradycardia or asystole. The half-life of adenosine in blood is very short, and side effects of adenosine infusion (when they occur) would quickly resolve when the infusion is discontinued. Administration of IV aminophylline or theophylline may be needed.

💬 Ask about this leaflet

Ask anything about Adenosine 30mg/10ml Solution for Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →